Bristol Myers Squibb (NYSE:BMY) Director Julia Haller Sells 3,800 Shares of Company Stock

Bristol Myers Squibb Company (NYSE:BMY) Director Julia Haller sold 3,800 shares of Bristol Myers Squibb stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the transaction, the director owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Bristol Myers Squibb Stock Down 1.5%

NYSE BMY traded down $0.93 during trading hours on Friday, hitting $62.20. 9,794,555 shares of the company were exchanged, compared to its average volume of 12,156,425. The company has a 50 day moving average of $62.34 and a two-hundred day moving average of $60.11. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 52-week low of $45.26 and a 52-week high of $68.64. The firm has a market cap of $127.15 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 0.32 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The business had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. During the same quarter last year, the business posted $1.63 EPS. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.45 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is currently 55.88%.

Analysts Set New Price Targets

BMY has been the topic of a number of analyst reports. Roth Capital began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target on the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 19th. Piper Sandler dropped their price objective on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a report on Monday, October 26th. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Finally, Leerink Partners lowered Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $73.00 to $59.00 in a research report on Monday, October 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $65.46.

Hedge Funds Weigh In On Bristol Myers Squibb

Large investors have recently bought and sold shares of the stock. Pinion Investment Advisors LLC increased its position in shares of Bristol Myers Squibb by 3.8% during the third quarter. Pinion Investment Advisors LLC now owns 4,316 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 158 shares in the last quarter. Altura Wealth Advisors Inc. grew its stake in Bristol Myers Squibb by 1.2% during the 3rd quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock worth $856,000 after buying an additional 161 shares during the last quarter. Capital City Trust Co. FL grew its stake in Bristol Myers Squibb by 0.7% during the 3rd quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock worth $1,455,000 after buying an additional 167 shares during the last quarter. Eagle Bay Advisors LLC increased its position in Bristol Myers Squibb by 2.6% during the third quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock worth $408,000 after buying an additional 168 shares during the period. Finally, Blue Bell Private Wealth Management LLC increased its position in Bristol Myers Squibb by 21.1% during the third quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 169 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.